What is ⁢Kaposi’s ⁢Sarcoma-Associated Herpesvirus (KSHV)?

Kaposi’s ⁣sarcoma is​ a cancer that develops from the cells that line blood or lymph vessels. It is often⁣ caused by the Kaposi’s sarcoma-associated herpesvirus⁢ (KSHV), also known as human Herpesvirus 8 (HHV-8). KSHV remains a important ‍health concern, ⁣notably for individuals living with HIV/AIDS, especially in regions like sub-Saharan Africa. Other groups at risk include transplant recipients and individuals with weakened ‍immune systems.

The Novel⁤ Gene Therapy Approach

The research,led by Yoshihiro izumiya,a professor in the UC Davis department of Biochemistry and⁤ Molecular Medicine and the Department of Dermatology, utilizes a specialized ‌gene therapy technique. This ​technique selectively targets and ⁢eliminates ​cancer cells infected with KSHV while preserving healthy cells.

The ⁢therapy employs⁢ a harmless virus, adeno-associated virus (AAV),‍ as a delivery vehicle.⁢ AAV carries a ⁣genetic payload‌ – a “Trojan horse” – into the infected cells. Crucially, the therapy leverages the virus’ own protein‍ to⁣ direct the therapeutic⁢ agents⁣ specifically into the cancer cells, inducing cell death.

The⁢ therapy’s selectivity stems from its ⁤design to activate only within cells harboring KSHV. ‌This activation is‍ triggered by a viral marker protein called LANA, which is​ uniquely present in KSHV-infected cells.

Preclinical Study Results

The ⁤study was conducted using mouse models‍ at UC ⁢Davis. Results demonstrated a significant ‍reduction in tumor growth with no detectable side effects.This finding is particularly encouraging, as many existing cancer treatments are associated with ample toxicity.